About Doctor
Dr. Rohit Swami
MD, DM (Medical Oncology)
Tata Memorial Hospital, Mumbai
Consultant Medical Oncology, Narayana Multispeciality Hospital, Jaipur
Dr. Rohit swami is a Senior Consultant Haematologist and Medical Oncologist in the Department of Medical Oncology at Narayana multispeciality Hospital in Jaipur, Rajasthan. After his MBBS from S.MS Medical College, he obtained an MD in Internal Medicine from Gandhi Medical College, Bhopal. This was followed by senior residency in medical oncology from sabdargunj hospital , New Delhi. Subsequently, Dr. Swami completed his DM Medical Oncology from Tata Memorial Hospital in Mumbai.
He worked for 1 year as Specialist registrar/consultant at TMH ,Mumbai and worked as Senior consultant medical oncology for 6 months at Shalby hospital ,Jaipur before moving on to his current posting.Dr.Rohit Swami has contributed several theses and research papers in the field of oncology. His expertise includes treatment of all kinds of cancers,including solid tumors and blood cancers in both adults and paediatric population.
Education
- MBBS – Swai Man Singh (SMS) Medical College, Jaipur, 2002 to 2008
- MD (Gen. Med) – Gandhi Medical College, Bhopal, 2010 to 2013
- DM (Med. Oncology) – Tata Memorial Hospital,Mumbai, 2014 to 2017
Work Experience
- MBBS – Swai Man Singh (SMS) Medical College, Jaipur, 2002 to 2008
- MD (Gen. Med) – Gandhi Medical College, Bhopal, 2010 to 2013
- DM (Med. Oncology) – Tata Memorial Hospital,Mumbai, 2014 to 2017
Fields of Expertise
- All types of cancers, tumours
- Solid Tumors & Blood Cancer
- Pediatric solid Tumors, & Haemato Oncology
- Chemotherapy, Targeted Therapy, Immunotherapy
- Palliative Therapy
- Bone Marrow Transplant
Research Projects
- Validation and use of the Hurria score in predicting chemotherapy toxicity risk in elderly population undergoing chemotherapy for Breast, GI and Gynaecological cancers in Indian setup.
- Prevalence of MMR status in locally advanced rectal cancer and its correlation with response to neoadjuvant therapy and survival.
- Multimodality management of periampullary adenocarcinomas – prognostic factors and outcomes.
Research Activities at Graduation & Post-Graduation Level
- “Study of prognostic significance of serum creatinine phosphokinase in Acute Poisoning cases”.
- “Prevalence of subclinical hypothyroidism is significantly higher in metabolic syndrome” ,Published in ISRA JIP
- “Subclinical hypothyroidism in metabolic syndrome increases cardiovascular morbidity” ,Published in ISRA JIP
- “Neuromyotonia :Clinical profile of ten cases from central India”
Awards & Presentations
- “Prevalence of subclinical hypothyroidism is significantly higher in metabolic syndrome”at 7TH National medicine update 2012, Bhopal, India
- “Study of prognostic significance of serum creatine phosphokinase in Acute Poisoning cases” at 8th National medicine update 2013, Bhopal, India
- “A randomised clinical trial evaluating the efficacy and safety of addition of oral metronomic chemotherapy after completion of standard chemo radiation versus observation in carcinoma oesophagus and gastro- oesophageal junction”.Presented at METRONOMICS @ MUMBAI 2016. 5th BIENNIAL INTERNATIONAL METRONOMIC & ANTI-ANGIOGENIC MEETING on 6-8 May 2016, in Mumbai, India
- “Good response to metronomic cyclophosphamide for metastatic epitheloid hemangioendothelioma: case report” Presented at METRONOMICS @ MUMBAI 2016. 5th BIENNIAL INTERNATIONAL METRONOMIC & ANTI-ANGIOGENIC MEETING on 6-8 May 2016, in Mumbai, India.
- “Gemcitabine–cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward”.Presented at 38th ICON meeting on 23-25 March 2018, inCochin, Kerala.
Publications
- Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib. Ramaswamy A, Bal M, Swami R, Shetty O, Bose S, Pai T, Gurav M, Gupta S, Ostwal V.Ann Transl Med. 2017 Mar;5(6):134. doi: 10.21037/atm.2017.03.31.
- Gemcitabine–cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward.Vikas Ostwal,Rohit Swami,Shraddha Patkar,Swaratika Majumdar,Mahesh Goel,Shaesta Mehta,Reena Engineer,Sarika Mandavkar,Suman Kumar,Anant Ramaswamy.
- Treatment practices in gastrointestinal (GI) neuroendocrine carcinoma (NEC) . Swami R, Ramaswamy A , V.Ostwal.Annals oncology 2018.(ESMO GI 2018).
- A randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.ASCO 2018.JCO 2018.
- Prevalence of subclinical hypothyroidism is significantly higher in metabolic syndrome. Swami R, Agrawal A, Jain R.K.International Standard Serial Number (ISSN): 2319.
- Subclinical hypothyroidism in metabolic syndrome increases cardiovascular morbidity.Swami R,Agrawal A,Barde R.R.
